Bio-Rad Laboratories/$BIO
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Bio-Rad Laboratories
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.
- Ticker
- $BIO
- Sector
- Health
- Primary listing
- NYSE
- Employees
- 7,450
- Headquarters
- Hercules, United States
- Website
- www.bio-rad.com
BIO Metrics
BasicAdvanced
$10B
10.05
$37.95
1.06
-
Price and volume
Market cap
$10B
Beta
1.06
52-week high
$396.23
52-week low
$236.73
Average daily volume
239K
Financial strength
Current ratio
3.177
Quick ratio
2.164
Long term debt to equity
0.122
Total debt to equity
0.179
Interest coverage (TTM)
5.02%
Profitability
EBITDA (TTM)
410.9
Gross margin (TTM)
52.19%
Net profit margin (TTM)
39.45%
Operating margin (TTM)
9.46%
Effective tax rate (TTM)
22.52%
Revenue per employee (TTM)
$350,000
Management effectiveness
Return on assets (TTM)
1.50%
Return on equity (TTM)
14.27%
Valuation
Price to earnings (TTM)
10.054
Price to revenue (TTM)
3.956
Price to book
1.35
Price to tangible book (TTM)
1.48
Price to free cash flow (TTM)
31.168
Free cash flow yield (TTM)
3.21%
Free cash flow per share (TTM)
12.242
Growth
Revenue change (TTM)
1.38%
Earnings per share change (TTM)
-254.52%
3-year revenue growth (CAGR)
-1.59%
10-year revenue growth (CAGR)
2.29%
3-year earnings per share growth (CAGR)
91.41%
10-year earnings per share growth (CAGR)
27.57%
What the Analysts think about BIO
Analyst ratings (Buy, Hold, Sell) for Bio-Rad Laboratories stock.
Analyst projections of the future price of Bio-Rad Laboratories stock.
Bulls say / Bears say
Digital PCR offers a growth engine: Bio-Rad said Q2 instrument revenue rose more than 20%, and new QX700 oncology assays broaden the platform’s research applications. (Bio-Rad Laboratories, Cambridge Network)
Restructuring could lift profitability: management targets $30 million to $35 million in annualised net savings and estimates 40 to 50 basis points of operating-margin expansion in 2027. (Investing.com)
Clinical Diagnostics provides a relatively resilient base: Q2 segment sales rose 2.6% reported, or 0.3% on a currency-neutral basis, led by quality systems, diabetes and blood typing. (Bio-Rad Laboratories)
Near-term growth remains weak: Bio-Rad’s 2026 outlook ranges from a 3% currency-neutral revenue decline to just 0.5% growth, with operating margin forecast at 10% to 12%. (Bio-Rad Laboratories)
Life Science is still contracting: Q2 sales fell 5.1% currency-neutral as academic research demand remained soft, particularly in the Americas. (SEC)
The turnaround has a near-term cost: Bio-Rad expects $80 million to $90 million in pre-tax restructuring charges, and the programme is not due to be substantially completed until the end of 2027. (SEC)
Data summarised monthly by Lightyear AI. Last updated on 3 Nov 2026.
BIO Financial Performance
Revenues and expenses
BIO Earnings Performance
Company profitability
Upcoming events
No upcoming events
BIO News
AllArticlesVideos
Funds containing BIO
AllUSDEURGBP
Fund name | Fund size | $BIO weighting |
|---|---|---|
iShares Healthcare Innovation€2B78 | $1.2B | 0.73% |
iShares Healthcare Innovation£DRDR | $1.3B | 0.73% |
iShares Healthcare Innovation$HEAL | $1.3B | 0.73% |
SPDR S&P 400 US Mid Cap$SPY4 | $6.4B | 0.20% |
SPDR S&P 400 US Mid Cap£SPX4 | $6.4B | 0.20% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.